Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug offers hope for breast cancer patients suffering from hot flashes

NCT ID NCT06917313

First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 36 times

Summary

This study tests a drug called fezolinetant to see if it can reduce hot flashes in women who have had breast cancer and are taking hormone therapy. About 92 women will be randomly assigned to receive either fezolinetant or a placebo daily for 12 weeks. The main goal is to measure how much the frequency of hot flashes decreases.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER EARLY STAGE BREAST CANCER (STAGE 1-3) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Ohio State University Comprehensive Cancer Center

    NOT_YET_RECRUITING

    Columbus, Ohio, 43201, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Yale University

    RECRUITING

    New Haven, Connecticut, 06511, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

The condition(s) this trial relates to.

breast cancer hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.